Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan 250012, China.
Neurosci Bull. 2008 Feb;24(1):39-44. doi: 10.1007/s12264-008-1107-1.
The immunotherapy for malignant glioma faces unique difficult, due to some anatomical and immunological characteristics including the existence of blood brain barrier, the absence of lymphatic tissues and dendritic cells (DCs) in the central nervous system (CNS) parenchyma, and the presence of an immunosuppressive microenvironment. Therefore, immunotherapeutic approaches will not be beneficial unless the compromised immune status in malignant glioma patients is overcome. DC-based immunotherapy, vaccinating cancer patients with DCs pulsed with various tumor antigens, is one of the most promising immunotherapeutic approaches for treatment of malignant glioma because it seems able to overcome, at least partially, the immunosuppressive state associated with primary malignancies. The preparation of DCs, choice of antigen, and route and schedule of administration are improving and optimizing with rapid development of molecular biology and gene engineering technology. DC vaccination in humans, after a number of pre-clinical models and clinical trials, would increase the clinical benefits for malignant glioma immunotherapy.
免疫疗法治疗恶性脑胶质瘤面临独特的困难，这是由于一些解剖学和免疫学特征，包括血脑屏障的存在、中枢神经系统实质中缺乏淋巴组织和树突状细胞（DCs），以及存在免疫抑制微环境。因此，除非克服恶性脑胶质瘤患者受损的免疫状态，否则免疫治疗方法不会有益。基于树突状细胞的免疫疗法，即用各种肿瘤抗原冲击树突状细胞来给癌症患者接种疫苗，是治疗恶性脑胶质瘤最有前途的免疫治疗方法之一，因为它似乎能够至少部分克服与原发性恶性肿瘤相关的免疫抑制状态。随着分子生物学和基因工程技术的快速发展，树突状细胞的制备、抗原的选择以及给药途径和方案正在不断改进和优化。经过一些临床前模型和临床试验后，在人类中进行树突状细胞疫苗接种将增加恶性脑胶质瘤免疫治疗的临床获益。
